Cross Country Healthcare (CCRN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
7 May, 2026Executive summary
Agreement reached to be acquired by Knox Lane, transitioning to a private company upon closing.
Transaction aims to provide immediate value to shareholders and enhance operational flexibility.
Leadership emphasizes continuity in mission, values, and commitment to employees and clients.
Forward-looking statements highlight anticipated benefits and strategic opportunities post-acquisition.
Voting matters and shareholder proposals
Shareholder approval required for the proposed merger with Knox Lane.
Proxy solicitation involves directors, executive officers, and related participants.
Board of directors and corporate governance
Board considered multiple factors, including culture and partnership, in approving the merger.
Directors and executive officers are participants in the proxy solicitation process.
Latest events from Cross Country Healthcare
- Merger and related compensation proposals approved, company to become a wholly owned subsidiary.CCRN
EGM 202617 Jul 2026 - Q3 2024 revenue fell 29% year-over-year, with margin pressure but strong cash and diversification.CCRN
Q3 20248 Jul 2026 - Q2 revenue dropped 37% with a net loss, but cash flow and liquidity remain strong.CCRN
Q2 20248 Jul 2026 - Shareholders to vote on a $13.25 per share cash merger, with board unanimous support.CCRN
Proxy filing15 Jun 2026 - Shareholders to receive $13.25 per share in cash in a board-approved merger, pending approvals.CCRN
Proxy filing3 Jun 2026 - Q1 2026 revenue dropped 17.8% and net loss widened, as merger plans to go private were announced.CCRN
Q1 20268 May 2026 - Shareholders to vote on $437M all-cash acquisition by Knox Lane, with no operational changes expected.CCRN
Proxy filing7 May 2026 - Transition to private ownership by Knox Lane at $13.25 per share, pending shareholder approval.CCRN
Proxy filing7 May 2026 - All shares to be acquired for $13.25 cash in a $437M deal, pending shareholder approval.CCRN
Proxy filing7 May 2026